Trial
NCT01089595
Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Fox Chase Cancer Center
Collaborators
Novartis
Condition
GIST
Intervention
Nilotinib
Why stopped
Novartis is ending their research program for Nilotinib in GIST.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-03-15